Saturday, November 14, 2026
ExploreSearch
Via News
MarketFX

USD/CNH Went Down By Over 1% In The Last 10 Sessions

Automated market report from our archive (2020–2024), published before source-traceability. How we work

USD/CNH Went Down By Over 1% In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.76% for the last 10 sessions. At 14:08 EST on Sunday, 17 March, USD/CNH (USDCNH) is $7.20.

USD/CNH's yearly highs and lows, it's 0% down from its 52-week low and 0% down from its 52-week high.

News about

  • Usd/jpy: scope to trend lower to 146.00 on a three-month view – rabobank. According to FXStreet on Friday, 15 March, "That said, despite the risk of a near-term pullback, we continue to see scope for USD/JPY to trend lower to 146.00 on a three-month view."
  • Usd/jpy extends upside to 149.00 as focus shifts to boj, fed policy. According to FXStreet on Friday, 15 March, "The USD/JPY climbs to 148.80 in the late European session on Friday as the Japanese Yen weakens on expectations that the Bank of Japan (BoJ) will not end the expansionary policy stance in the meeting on Tuesday."

More news about USD/CNH (USDCNH).

Categories

MarketFX

Tags

ForexForeign Exchange MarketCurrenciesUSDCNHUSD/CNHPrice DownFOREX Price DownForex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com